HUAOTA BIOPHARM
Shanghai Huaota Biopharm is a wholly owned subsidiary of Huahai Pharmaceuticals and was established in September 2013. Huaota is dedicated to develop high quality biological drugs for global market to meet the demand of availability and affordability for high-end biological products from global patients. Huaota employs the state-of-the-art biopharmaceutical manufacturing technology and equipments to build production line meeting the GMP requirement from CFDA, US FDA and EU EMA. Huaota currently has one 200L and one 1000L disposable bioreactor and two fill-and-finish lines to support both prefilled syringe and vial filling.
HUAOTA BIOPHARM
Industry:
Biopharma Biotechnology Health Care Manufacturing Medical
Founded:
2013-09-10
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.huaota.com
Total Employee:
251+
Status:
Active
Contact:
86-021-51320756
Total Funding:
3 M CNY
Technology used in webpage:
Euro Pound Sterling Japanese Yen China Telecom Amap
Current Employees Featured
Zhu Xiangyang CEO @ Huaota Biopharm
CEO
Investors List
Huahai Yaoye
Huahai Yaoye investment in Angel Round - Huaota Biopharm
Official Site Inspections
http://www.huaota.com
- Host name: 112.64.166.220.broad.dy.sc.dynamic.163data.com.cn
- IP address: 220.166.64.112
- Location: China
- Latitude: 30.6667
- Longitude: 104.0667
- Timezone: Asia/Shanghai
More informations about "Huaota Biopharm"
上海华奥泰生物药业股份有限公司-关于我们
Over the years, Huaota has completed many science and technology projects in collaboration with universities, research institutes, and other research organizations in China and globally. In 2019, Huaota was certified as High- …See details»
上海华奥泰生物药业股份有限公司 - huaota.com
Shanghai Huaota Biopharmaceutical Co., Ltd. (aka ‘Huaota’) was established in September 2013. Huaota is a subsidiary of Zhejiang Huahai Pharmaceutical Co., Ltd. Driven by innovation and …See details»
Huaota Biopharm - Crunchbase Company Profile & Funding
Shanghai Huaota Biopharm is a wholly owned subsidiary of Huahai Pharmaceuticals and was established in September 2013. Huaota is dedicated to develop high quality biological drugs …See details»
Shanghai Huaaotai Biopharmaceutical Co., Ltd. - Drug ... - Patsnap
Www.huaota.com. Subsidiary Company | 2013 | Shanghai Shi, China | 250-500 | www.huaota.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational Medicine. …See details»
Huaota Biopharm - Funding, Financials, Valuation & Investors
Huaota Biopharm develops high-quality biological drugs for the global market. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. ...See details»
Huabo Biopharm (Shanghai) Co., Ltd.-新闻资讯
Shanghai, 17 Dec 2021 – Shanghai Huaota Biopharmaceutical Co., Ltd (“Huaota”) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New D... Press Releases. 09. 2021-12. FIH …See details»
Huabo Biopharm (Shanghai) Co., Ltd.-新闻资讯
Huaota Commits to Develop Innovative Drugs for Treatment of Oncology and Autoimmune Diseases. In 2021, Huaota had 4 projects in preparation for clinical research application (IND), including HB0028 (PD-L1/TGF-β), HB0036 (PD …See details»
Shanghai Huaaotai Biopharmaceutical Co., Ltd.
了解Shanghai Huaaotai Biopharmaceutical Co., Ltd. (上海华奥泰生物药业股份有限公司)公司的药物管线,治疗领域,技术平台,以及它的48项临床试验, 134篇新闻和9篇文献,疾病领域:肿 …See details»
华奥泰-动脉网 - vbdata.cn
Sep 10, 2013 上海华奥泰生物药业股份有限公司(以下简称 “华奥泰”)成立于2013年9月,为浙江华海药业股份有限公司的子公司。自成立以来,华奥泰持续专注于创新与发展,已建成完善 …See details»
Huaota Biopharm - Tech Stack, Apps, Patents & Trademarks
Huaota Biopharm develops high-quality biological drugs for the global market.See details»
上海华奥泰生物药业股份有限公司-新闻资讯 - huaota.com
Shanghai Huaota Biopharmaceutical Co., Ltd. (hereinafter referred to as "Huaota") received FDA approval for the anti-PD-L1/TIGIT bispecific antibody (project code HB0036),... Press …See details»
Medicilon Assists Huaota's CD73-targeting ADC approved for …
Recently, Shanghai Huaota Biopharmaceutical Co., Ltd. (Huaota) received a notification from the US FDA, agreeing that the third-generation antibody drug conjugate (ADC) project HB0052 …See details»
Huaota Biopharm - Contacts, Employees, Board Members
Organization. Huaota Biopharm . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. …See details»
Focusing on Cancer and Autoimmune Diseases: Huaota ... - Huabo …
Jul 2, 2021 At Huaota, we aim for rapid development of novel biologics targeting cancer, autoimmune diseases and inflammatory diseases” Said Dr. Xiangyang Zhu, CEO of Shanghai …See details»
华博生物与云检医学达成战略合作 - huaota.com
May 7, 2024 华博生物与云检医学达成战略合作 共同推进创新药物生物标志物开发与研究. 2024年4月26日,上海华奥泰生物药业股份有限公司子公司,华博生物医药技术(上海)有限 …See details»
IND of HB0036 Approved by FDA - Huabo Bio
HB0036 is the second bispecific antibody developed by Huaota. It binds to PD-L1 and TIGIT with high specificity and affinity. It has strong anti-tumor effect by blocking both PD-1/PD-L1 and …See details»
HB0036 in NSCLC and Advanced Solid Tumor - ICH GCP
May 30, 2022 May 8, 2023 updated by: Shanghai Huaota Biopharmaceutical Co., Ltd. A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, …See details»
上海华奥泰生物药业股份有限公司-喜讯!华奥泰自主研发的TSLP/I…
5 days ago 药物警戒部门联系方式: 公共联系电话: 150 2649 8629. 药物警戒邮箱: pvhuaota@huaota.comSee details»
Huaota Certified as Enterprise Research Institute By Science ...
Shanghai, 13 Jan 2021 – Shanghai Huaota Biopharmaceutical Co., Ltd (“Huaota”) today announced that it has been certificated by the Science, Technology and Economy …See details»